EP1244636A1 - Benzimidazoles, production thereof and the use thereof as antithrombotic - Google Patents

Abstract

The invention relates to novel benzimidazoles of general formula (I), wherein Ra to Rc have the meanings given in claim no.1, to their tautomers, their stereoisomers, their mixtures, their prodrugs, their derivatives containing a group which has been negatively charged under physiological conditions instead of a carboxy group; and their salts, especially their physiologically compatible salts with inorganic or organic acids or bases; with valuable properties. The compounds of general formula (I) wherein Rc does not represent an amidino group, are valuable intermediate products for producing amidino compounds of general formula (I) which have valuable pharmacological properties, especially an antithrombotic effect.

Description

 BENZ IMIDAZ OLE, THEIR PRODUCTION AND THEIR USE AS ANTITHROMBOTICS

The present invention relates to benzimidazoles of the general formula

their tautomers, their stereoisomers, their mixtures, their prodrugs, their derivatives which, instead of a carboxy group, contain a group which is negatively charged under physiological conditions, and their salts, in particular their physiologically tolerable salts with inorganic or organic acids or bases, which have valuable properties ,

The compounds of the above general formula I in which R _{a is} a straight-chain C _{1 -3} alkyl group which is in the 1-position by an optionally by a C ₁ . _3- alkyl group substituted pyrrolidinocarbonyl or 2, 5-dihydropyrrolocarbonyl group and by an amino group which is monosubstituted by a cyano-C ^ alkyl group, and / or R _{c is} a cyano group or in the 5-position by a C ^ alkyl or Phenyl group substituted 1, 2, 4-oxadiazol-3-yl group, where the phenyl substituent can be substituted by a fluorine, chlorine or bromine atom or by a C ^ alkyl group, are valuable intermediates for the preparation of the other compounds of the general Formula I, and the compounds of the general formula I above, in which R _{c represents} one of the following amidino groups, and their tautomers, their stereoisomers, their mixtures, their prodrugs, their derivatives, which instead of a carboxy group is a negatively charged under physiological conditions group contain, and their salts, especially their physiologically compatible salts with inorganic or organic salts, and their stereoisomers have valuable pharmacological properties, in particular an antithrombotic effect.

The present application thus relates to the new compounds of the above general formula I and their preparation, the pharmaceutical compositions containing the pharmacologically active compounds, their preparation and use.

In the general formula above means

R _{a is} a straight chain C ₁ . ₃ alkyl group in which the

Hydrogen atoms can be replaced in whole or in part by fluorine atoms and in the 1-position

by a pyrrolidinocarbonyl or 2, 5-dihydropyrrolocarbonyl group optionally substituted by a C ₁ _ ₃ alkyl group and

by an amino group which is monosubstituted by a carboxy-C _1-4 -alkyl, cyano-C ₁ " ₄ -alkyl or tetrazolyl-C _1-4 -alkyl group,

or by a C 1-4 alkyl group which is terminated by a C _1, optionally on one or both amine nitrogen atoms. ₃ -alkyl groups substituted by N- (carboxy-C _{1, 3} -alkylaminocarbonyl) - amino group, by a carboxy-C ₁ . ₃ -alkoxy-, N- (carboxy-C _{1, 3} -alkyl) -amino-, N- (C ^ -alkyl) -N- (carboxy-C ^ -alkyl) -amino-, N- (carboxy-C ^ alkylsulfonyl) amino, N- (C _{L. 3} alkyl) -N- (carboxy-C ^ alkylsulfonyl) amino or tetrazolyl-C ^ alkyl group is substituted,

R _{b is} a C ^ alkyl group and R _{c is} an amidino group, a cyano group or a 5-position through a C ₁ . _3- alkyl or phenyl group substituted 1,2,4-oxadiazol-3 -yl group, where the phenyl substituent can be substituted by a fluorine, chlorine or bromine atom or by a C 1-4 alkyl group.

The carboxy groups mentioned in the definition of the abovementioned radicals can also be replaced by a group which can be converted into a carboxy group in vivo or by a group which is negatively charged under physiological conditions, or

the amino and imino groups mentioned in the definition of the radicals mentioned above can also be substituted by a radical which can be split off in vivo. Such groups are described, for example, in WO 98/46576 and by N.M. Nielson et al. in International Journal of Pharmaceutics 23, 75-85 (1987).

Among a group which can be converted into a carboxy group in vivo is, for example, a hydroxmethyl group, a carboxy group esterified with an alcohol, in which the alcoholic part is preferably one a phenyl C ₁ . _3- alkanol, a C ₃ _ ₅ cycloalkanol, where a C ₅ _ ₈ cycloalkanol may additionally be substituted by one or two C _1-3 alkyl groups, a C _s . _8- Cycloalkanol, in which a methylene group in the 3- or 4-position by an oxygen atom or by an optionally by a C ^ alkyl, phenyl-C ^ alkyl, phenyl-C ₁ _ ₃ alkoxycarbonyl or C ₂ . ₆ -alkanoyl group substituted imino group and the cycloalkanol part can additionally be substituted by one or two C ^ alkyl groups, a C ₄ . ₇ -cycloalkenol, a C ₃ . _5- alkenol, a phenyl-C ₃ . _s -alkenol, a C ₃ . ₅ -alkinol or phenyl- C ₃ . ₅ -alkynol, with the proviso that no bond to the oxygen atom starts from a carbon atom which carries a double or triple bond, a C ₃ _ C _B cycloalkyl. _{1 3-} alkanol, a bicycloalkanol with a total of 8 to 10 carbon atoms, which is additionally in the bicycloalkyl part by a or two C ₁ . ₃ -alkyl groups can be substituted, a 1, 3 -Di - hydro- 3 -oxo-l -isobenzfuranol or an alcohol of the formula

R _d -C0-0- (R _e CR _f ) -OH,

by doing

R _{d is} a C 1-4 alkyl, C ₅ . ₇ - cycloalkyl -, phenyl - or phenyl -

C ₁ . ₃ -alkyl group,

R _{e is} a hydrogen atom, a C ₁ . ₃ -alkyl-, C _s . _7- cycloalkyl or phenyl group and

R _{f represents} a hydrogen atom or a, - alkyl group,

under a group negatively charged under physiological conditions, such as a tetrazol-5-yl, phenylcarbonylaminocarbonyl, trifluoromethylcarbonylaminocarbonyl, nylamino, phenylsulfonylamino, benzylsulfonylamino, trifluoromethylsulfonylamino, C- ^ g-alkylsulfonylaminocarbonyl, phenylsulfonylaminocarbonyl, benzylsulfonylaminocarbonyl or perfluoro-C ^ g-alkylsulfonylaminocarbonyl group

and under a residue which can be split off from an imino or amino group in vivo, for example a hydroxyl group, an acyl group such as one optionally by fluorine, chlorine, bromine or iodine atoms, by C _1-3 alkyl or C _1-3 alkoxy groups mono- or disubstituted benzoyl group, where the substituents may be the same or different, a pyridinoyl group or such as the formyl, acetyl, propionyl, butanoyl, pentanoyl or hexanoyl group, a 3, 3, 3-trichloropropionyl or allyloxycarbonyl group, a C- _L . _j g-alkoxycarbonyl or in which hydrogen atoms can be replaced in whole or in part by fluorine or chlorine atoms, such as methoxycarbonyl, ethoxycarbonyl, propoxycarbonyl, isopropoxycarbonyl, butoxycarbonyl, tert. Butoxycarbonyl, pentoxycarbonyl, hexoxycarbonyl, octyloxycarbonyl, nonyloxycarbonyl, decyloxycarbo- nyl-, undecyloxycarbonyl-, dodecyloxycarbonyl-, hexadecyloxy- carbonyl-, methylcarbonyloxy-, ethylcarbonyloxy-, 2,2,2-trichloroethylcarbonyloxy-, propylcarbonyloxy-, isopropylcarbonyl- oxy-, butylcarbonyloxy-, tert. butylcarbonyloxy-, pentylcarbo- nyloxy -, Hexylcarbonyloxy, octylcarbonyloxy, nonylcarbonyloxy, decylcarbonyloxy, undecylcarbonyloxy, dodecylcarbonyloxy or hexadecylcarbonyloxy group, a phenyl-C- _L . _g -alkoxycarbonyl group such as the benzyloxycarbonyl, phenylethoxycarbonyl or phenylpropoxycarbonyl group, a 3-aminopropionyl group in which the amino group passes through or C ₃ . _7- cycloalkyl groups mono- or disubstituted and the substituents can be the same or different, a C - ^ - alkylsulfonyl- C _2-4 alkoxycarbonyl-, C ₁ . ₃ -alkoxy-C ₂ . ₄ -alkoxy-C _2-4 -alkoxycarbonyl-, R _d -CO-0- (R _d CR _f ) -O-CO-, (R _g CR _h ) -0-C0- or C ^ _g -alkyl-CO-O- (R _g CR _h ) - (R _g CR _h ) -O-CO group, in which R _d to R _{f are} like are defined above,

R _g and R _h , which may be the same or different, are hydrogen atoms or C ₁ . Represent ₃ alkyl groups,

to understand.

Furthermore, the definition of the above-mentioned saturated alkyl and alkoxy parts which contain more than 2 carbon atoms also include their branched isomers such as the isopropyl, tert-butyl, isobutyl group etc.

Preferred compounds of the general formula I mentioned above are those in which

R _b and R _{c are} as defined above and

R _{a is defined} with the proviso that a substituent represents an unbranched C _1-3 alkyl group or a 2,5-dihydropyrrolocarbonyl group which is optionally substituted by a C 1-4 alkyl group, or R _{a is} an ethyl group which is in the 1-position

by a pyrrolidinocarbonyl group and

is substituted by an amino group, the amino group being substituted by an ethoxycarbonylmethyl group which is substituted in the 2-position by a methoxy, dimethylamino or tolyl group by a carboxymethyl, C ₃ . ₄ -Alkoxycarbonylmethyl-, cyclohexyloxycarbonyl methyl-, 3- (C. _{2 3} alkoxycarbonyl) propyl or tetrazolyl methyl group is substituted,

R _{b is} a methyl group and

R _c is an amidino group substituted by a benzoyl, methylbenzoyl, fluorobenzoyl or trifluoromethylbenzoyl group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group substituted in the 2-position by a methyl group and

is substituted by an amino group, the amino group being substituted by a carboxymethyl or ethoxycarbonylmethyl group,

R _{b is} a methyl group and

R _{c is} an amidino group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group and by an amino group substituted by a carboxymethyl, C ₃ _ ₄ -alkoxycarbonylmethyl or tetrazolylmethyl group or

is substituted by a methyl group, the methyl group being substituted by a tetrazolyl, carboxymethoxy, ethoxycarbonylmethoxy, ethoxycarbonylethylamino, N- (2-carboxyethyl) -N-methylamino, N- [2- (C ^ -Alkoxycarbonyl) -ethyl] - N-methylamino-, N- (carboxymethylaminocarbonyl) -N-methylamino-, N- (C ^ -alkoxycarbonylmethylaminocarbonyl) -N-methylamino-, N- (carboxymethylsulfonyl) -N-methyl- amino or N- (C _{1, 3} -alkoxycarbonylmethylsulfonyl) -N-methylamino group is substituted,

R _{b is} a methyl group and

R _{c represents} an amidino group,

their tautomers, their isomers and their salts.

Particularly preferred compounds of the general formula I above are the compounds of general formula I mentioned above with the exception of

(1) 2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (n-butyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole and

(2) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (tetrazol-5-yl-methylmino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole,

their tautomers, their isomers and their salts.

Very particularly preferred compounds of the general formula I above are those in which

R _{a is} an ethyl group in the 1-position by a 2, 5-dihydropyrrolocarbonyl group optionally substituted by a methyl group and

by an amino group which is replaced by a C ₁ . ₄ -alkoxycarbonyl- C _x . ₄ -alkyl group in which the C ₂ . ₄ -alkoxy part may be terminally substituted by a methoxy, dimethylamino, phenyl or tolyl group, by a carboxy-C ₁ . ₄ -alkyl-, cyclohexyloxycarbonyl-C ₁ . ₄ -alkyl or tetrazolyl- C 1-4 alkyl group is monosubstituted, or

by a C _τ _ ₂ alkyl group which is terminated by an N- (carboxy-C 1-4 -alkylaminocarbonyl) amino or N- which is optionally substituted on one or both amine nitrogen atoms by a C _1-3 alkyl group (C _{1, 3} -alkoxycarbonyl-C _{1, 3} -alkylaminocarbonyl) amino group, by a carboxy-C ₁ . ₃ -alkoxy-, C ₁ _ ₃ -alkoxycarbonyl-C ₁ _ ₃ -alkoxy-, N- (C _{1. 3} -alkyl) -N- (carboxy-C ^ -alkyl) -amino-, N- ( C ^ alkyl) - N- (C ₁ _ ₃ -alkoxycarbonyl-C ₁ .. ₃ -alkyl) -amino-, N- (C ^ -alkyl) - N- (carboxy-C ₁ _ ₃ -alkylsulfonyl) - amino or N- (C ₁ _. ₃ -alkyl) - N- (C _{j ^} ^ -alkoxycarbonyl-Ci ^ -alkylsulfonyl) -amino- or tetrazolyl-C- _{L. 3} -alkyl group is substituted,

R _{b is} a methyl group and

R _c is an amidino group which may be substituted by a benzoyl, methylbenzoyl, fluorobenzoyl or trifluoromethylbenzoyl group

or R _{a is} an ethyl group which is in the 1-position

by a pyrrolidinocarbonyl group and

is substituted by an amino group, the amino group by an ethoxycarbonylmethyl group which is substituted in the 2-position by a methoxy, dimethylamino or tolyl group by a carboxymethyl, propyl oxycarbonylmethyl-, Isopropyloxycarbonylmethyl-, oxycarbonylmethyl- isobutyl, cyclohexyloxycarbonylmethyl, 3- (C. _{2 3} alkoxycarbonyl) propyl or tetrazolylmethyl group is substituted,

R _{b is} a methyl group and

R _c is an amidino group substituted by a benzoyl, methylbenzoyl, fluorobenzoyl or trifluoromethylbenzoyl group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group substituted in the 2-position by a methyl group and

is substituted by an amino group, the amino group being substituted by a carboxymethyl or ethoxycarbonylmethyl group,

R _{b is} a methyl group and

R _{c is} an amidino group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group and

by one by a carboxymethyl or C ₃ . ₄ -alkoxycarbonylamino group substituted amino group or

is substituted by a methyl group, the methyl group being replaced by a tetrazolyl, carboxymethoxy, ethoxycarbonyl methoxy, ethoxycarbonylmethylamino, N- (2-carboxyethyl) -N-methylamino, N- [2- (C ₁ _ ₃ -alkoxycarbonyl) -ethyl] - N-methylamino-, N- (carboxymethylaminocarbonyl) -N-methylamino-, N- (C ^ -alkoxycarbonylmethylaminocarbonyl) -N-methyl- amino, N- (carboxymethylsulfonyl) -N-methylamino or N- (C ^ -alkoxycarbonylmethylsulfonyl) -N-methylamino group is substituted,

R _{b is} a methyl group and

R _{c represents} an amidino group,

their tautomers, their isomers and their salts.

The following may be mentioned as particularly preferred compounds:

(1) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole,

(2) 2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolo-carbonyl) ethyl] benzimidazole,

(3) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (isobutyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole,

(4) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (n-propyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole,

(5) (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- [(R, S) -1-methylpyrrolidinocarbonyl] ethyl] benzimidazole .

(6) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole and (7) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (cyclohexyloxycarbonylmethylamino) -1- (2,5-di-hydropyrrolocarbonyl) ethyl] benzimidazole .

their isomers and their salts.

According to the invention, the compounds of general formula I are obtained by processes known per se, for example by the following processes:

a) For the preparation of a compound of general formula I, in which R _{c is} a cyano group or a 1, 2, 4-oxadiazole-3 -yl group substituted in the 5-position by a C 1-4 alkyl or phenyl group, the Phenyl substituent can be substituted by a fluorine, chlorine or bromine atom or by a C _1-3 alkyl group:

Cyclization of any compound of the general formula formed in the reaction mixture

in the

R _a and R _b are defined as mentioned at the beginning,

R _c 'is a cyano group or a 1, 2, 4-oxadiazol-3-yl ~ group substituted in the 5-position by a C _1.3 alkyl or phenyl group, the phenyl substituent being substituted by a fluorine, chlorine or bromine atom or by a C ^ alkyl group can be substituted,

Z _x and Z ₂ , which can be the same or different, optionally substituted by alkyl groups having 1 to 6 carbon atoms, amino, hydroxyl or mercapto groups or Z ₁ and Z ₂ , together represent an oxygen or sulfur atom, an imino group optionally substituted by an alkyl group having 1 to 3 carbon atoms, an alkylenedioxy or alkylenedithio group each having 2 or 3 carbon atoms.

The cyclization is conveniently carried out in a solvent or solvent mixture such as ethanol, isopropanol, glacial acetic acid, benzene, chlorobenzene, toluene, xylene, glycol, glycol monomethyl ether, diethylene glycol dimethyl ether, sulfolane, dimethylformamide, tetralin or in an excess of those used to prepare the compound of the general Formula II used acylating agents, for example in the corresponding nitrile, anhydride, acid halide, ester or amide, for example at temperatures between 0 and 250 ° C., but preferably at the boiling point of the reaction mixture, if appropriate in the presence of a condensing agent such as phosphorus oxychloride, thionyl chloride, sulfonyl chloride, sulfuric acid, p -Toluenesulfonic acid, methanesulfonic acid, hydrochloric acid, phosphoric acid, polyphosphoric acid, acetic acid, acetic anhydride, N, N-dicyclohexyl-carbodiimide or optionally also in the presence of a base such as potassium ethylate or potassium tert-butylate. However, the cyclization can also be carried out without a solvent and / or condensing agent.

b) For the preparation of a compound of the general formula I in which R _{c represents} an amidino group:

Reaction of a compound of the general formula optionally formed in the reaction mixture

in the R _a and R _b are defined as mentioned at the outset and Z _{4 is} an alkoxy or aralkoxy group such as the methoxy, ethoxy, n-propoxy, isopropoxy or benzyloxy group or an alkylthio or aralkylthio group such as the methylthio, ethylthio represents n-propylthio or benzylthio group, with ammonia or with its salts.

The reaction is advantageously carried out in a solvent such as methanol, ethanol, n-propanol, tetrahydrofuran or dioxane at temperatures between 0 and 150 ° C, preferably at temperatures between 0 and 80 ° C, with ammonia or one of its salts such as ammonium carbonate or ammonium acetate ,

A compound of the general formula III is obtained, for example, by reacting a corresponding cyano compound with a corresponding alcohol such as methanol, ethanol, n-propanol, isopropanol or benzyl alcohol in the presence of an acid such as hydrochloric acid or by reacting a corresponding amide with a trialkyloxonium salt such as triethyloxonium tetrafluoroborate in a solvent such as methylene chloride, tetrahydrofuran or dioxane at temperatures between 0 and 50 ° C, but preferably at 20 ° C, or a corresponding nitrile with hydrogen sulfide, advantageously in a solvent such as pyridine or dimethylformamide and in the presence of a base such as Triethylamine and subsequent alkylation of the thioamide formed with an appropriate alkyl or aralkyl halide.

c) To prepare a compound of the general formula I in which R _a contains a carboxy group and R _c is defined as mentioned at the beginning:

Conversion of a compound of the general formula in the

R _b and R _c are defined as mentioned at the beginning and

R _a 'has the meanings mentioned for R _a with the proviso that R _a contains a group which can be converted into a carboxy group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis,

by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis in a compound of general formula I, in which R _a contains a carboxy group, is converted.

A group which can be converted into a carboxy group is, for example, a carboxyl group protected by a protective radical, such as its functional derivatives, e.g. B. their unsubstituted or substituted amides, esters, thioesters, trimethylsilyl esters, orthoesters or imino esters, which are expediently converted into a carboxyl group by means of hydrolysis,

their esters with tertiary alcohols, e.g. the tert-butyl ester, which are expediently converted into a carboxyl group by treatment with an acid or thermolysis, and

their esters with aralkanols, e.g. the benzyl ester, which are expediently converted into a carboxyl group by means of hydrogenolysis.

The hydrolysis is advantageously carried out either in the presence of an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or a mixture thereof or in the presence of a base such as lithium hydroxide, Sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water / methanol, water / ethanol, water / isopropanol, methanol, ethanol, water / tetrahydrofuran or water / dioxane at temperatures between -10 and 120 ° C, for example at temperatures between room temperature and Boiling temperature of the reaction mixture carried out.

If a compound of the formula IV contains, for example, the tert-butyl or tert-butyloxycarbonyly group, these can also be treated by treatment with an acid such as trifluoroacetic acid, formic acid, p-toluenesulfonic acid, sulfuric acid, hydrochloric acid, phosphoric acid or polyphosphoric acid, optionally in an inert solvent such as methylene chloride, Chloroform, benzene, toluene, diethyl ether, tetrahydrofuran or dioxane preferably at temperatures between -10 and 120 ° C, for example at temperatures between 0 and 60 ° C, or also thermally optionally in an inert solvent such as methylene chloride, chloroform, benzene, toluene, tetrahydrofuran or dioxane and preferably in the presence of a catalytic amount of an acid such as p-toluenesulfonic acid, sulfuric acid, phosphoric acid or polyphosphoric acid preferably at the boiling point of the solvent used, for example at temperatures between 40 and 120 ° C, split off.

If a compound of the formula IV contains, for example, the benzyloxy or benzyloxycarbonyl group, these can also be hydrogenolytically in the presence of a hydrogenation catalyst such as palladium / carbon in a suitable solvent such as methanol, ethanol, ethanol / water, glacial acetic acid, ethyl acetate, dioxane or dimethylformamide preferably at temperatures between 0 and 50 ° C, for example at room temperature and a hydrogen pressure of 1 to 5 bar.

d) For the preparation of a compound of the general formula I in which R _{c represents} an amidino group which is substituted by a radical which can be split off in vivo: Implementation of a compound of the general formula

in the

R _a and R _b are defined as mentioned above, with a compound of the general formula

Z ₅ - R ₉ (VII),

in the

R _{9 is} the acyl residue of one of the residues which can be cleaved in vivo and

Z _{5 is} a nucleofugic leaving group such as a halogen atom, for example a chlorine, bromine or iodine atom, or a p-nitrophenyl group.

The reaction is preferably carried out in a solvent such as methanol, ethanol, methylene chloride, tetrahydrofuran, toluene, dioxane, dimethyl sulfoxide or dimethylformamide, optionally in the presence of an inorganic or a tertiary organic base, preferably at temperatures between 20 ° C. and the boiling point of the solvent used.

With a compound of the general formula VII, in which Z _{5 represents} a nucleofugic leaving group, the reaction is preferably carried out in a solvent such as methylene chloride, acetonitrile, tetrahydrofuran, toluene, acetone / water, dimethylformamide or dimethyl sulfoxide, optionally in the presence of a base such as sodium hydride, Potassium carbonate, potassium tert-butoxide or N-ethyl-diisopropylamine at temperatures between 0 and 60 ° C, performed. e) For the preparation of a compound of the general formula I in which R _{c represents} one of the amidino groups mentioned at the outset:

Catalytic hydrogenation of a compound of the general formula

in the

R _a and R _b are defined as mentioned at the outset and R _c "represents a 1, 2, 4-oxadiazol-3-yl group substituted in the 5-position by a C 1-4 alkyl or phenyl group, in which the phenyl substituent is represented by a Fluorine, chlorine or bromine atom or can be substituted by a C _x _ ₃ alkyl group, and if necessary subsequent hydrolysis of a compound obtained in this way.

The catalytic hydrogenation is preferably carried out in a suitable solvent such as methanol, ethanol, ethanol / water, glacial acetic acid, ethanol / glacial acetic acid, ethyl acetate, dioxane or dimethylformamide in the presence of a hydrogenation catalyst such as palladium / carbon, preferably at temperatures between 0 and 50 ° C, e.g. at room temperature, and a hydrogen pressure of 1 to 5 bar.

The optionally subsequent hydrolysis is expediently carried out either in the presence of an acid such as hydrochloric acid, sulfuric acid, phosphoric acid, acetic acid, trichloroacetic acid, trifluoroacetic acid or mixtures thereof or in the presence of a base such as lithium hydroxide, sodium hydroxide or potassium hydroxide in a suitable solvent such as water, water / methanol, Water / ethanol, water / isopropanol, methanol, ethanol, water / tetrahydrofuran or water / dioxane at temperatures between -10 and 120 ° C, eg at temperatures between room temperatures rature and the boiling temperature of the reaction mixture.

f) For the preparation of a compound of general formula I in which R _{a represents} an amino-C _1-3 alkyl group in which the amino group is replaced by a carboxy-C ₁ . ₄ -alkyl or tetrazolyl- C ₁ , _i -alkyl group is monosubstituted:

Alkylation of a compound of the general formula

in the

R _b and R _c are defined as mentioned at the beginning and

R _a "represents an amino-C _1-3 alkyl group, with a compound of the general formula

R _a "'- Z ₇ (X)

in the

R _a "'is a carboxy-C _{1. 4,} alkyl or tetrazolyl-C ₁ _ ₄ alkyl group and

Z _{7 represents} a nucleofugic leaving group such as a halogen atom or a sulfonic acid ester residue, for example a chlorine, bromine or iodine atom, or a p-nitrophenyl group.

The alkylation is conveniently carried out in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethyl sulfoxide, dimethylformamide or acetone, optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N-ethyl diisopropylamine or N-methyl-morpholine, which can also serve as a solvent at the same time, or optionally in the presence of silver carbonate or silver oxide at temperatures between -30 and 100 ° C, but preferably at temperatures between -10 and 80 ° C.

If, according to the invention, a compound of the general formula I is obtained in which R _a contains a carboxy group, this can then be converted by esterification into a corresponding compound in which R _{a contains} an esterified carboxy group, and / or

a compound of the general formula I in which R _{a contains} an esterified carboxy group, this can then be converted by transesterification into a corresponding compound in which R _a contains another esterified carboxy group and / or

a compound of the general formula I in which R _a contains a cyano group, this can then be converted into a corresponding compound in which R _a contains a tetrazolyl group.

The subsequent esterification is conveniently carried out with an appropriate alcohol in a solvent or solvent mixture such as methylene chloride, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane, but preferably in an excess of the alcohol used, optionally in the presence of an acid such as hydrochloric acid or in the presence of a dehydrating agent, for example in the presence of isobutyl chloroformate, thionyl chloride, trimethylchlorosilane, hydrochloric acid, sulfuric acid, methanesulfonic acid, p-toluenesulfonic acid, phosphorus trichloride, phosphorus pentoxide, N, N'-dicyclohexylcarbodiimide, N, N'-carbodiimide Hydroxysuccinimide, N, N '-carbonyldiimidazole- or N, N'-thionyldiimidazole, triphenylphosphine / carbon tetrachloride or triphenylphosphine / diethyl azodicarboxylate, optionally in the presence of a base such as potassium carbonate, N-ethyl-diisopropylamine or N-N-dimidinamino moderately at temperatures between 0 and 150 ° C, preferably at temperatures between 0 and 80 ° C, or with a corresponding halide in a solvent such as methylene chloride, tetrahydrofuran, dioxane, dimethyl sulfoxide, dimethylformamide or acetone, optionally in the presence of a reaction accelerator such as sodium or potassium iodide and preferably in the presence of a base such as sodium carbonate or potassium carbonate or in the presence of a tertiary organic base such as N-ethyl-diisopropylamine or N-methyl-morpholine, which can also serve as a solvent, or optionally in the presence of silver carbonate or silver oxide at temperatures between -30 and 100 ° C, but preferably at temperatures between -10 and 80 ° C.

The subsequent transesterification is advantageously carried out with an appropriate alcohol in a solvent or solvent mixture such as methylene chloride, benzene, toluene, chlorobenzene, tetrahydrofuran, benzene / tetrahydrofuran or dioxane, but preferably in an excess of the alcohol used, advantageously in the presence of an acid such as hydrochloric acid or in Presence of a compound such as 2, 8, 9-trimethyl-l-phospha- 2, 5, 8, 9-tetraazabicyclo [3.3.3] undecane at temperatures between 0 and 150 ° C, preferably at temperatures between 0 and 80 ° C, carried out.

The subsequent conversion of a cyano group into a tetrazolyl group is preferably carried out in a solvent such as benzene, toluene or dimethylformamide at temperatures between 80 and 150 ° C., preferably at 120 and 130 ° C. In this case, the required hydrochloric acid is expediently released during the reaction from an alkali azide, for example from sodium azide, in the presence of a weak acid such as ammonium chloride. The reaction can also be carried out with another salt or derivative of nitrogenous hydrochloric acid, preferably with aluminum azide or tributyltin azide, in which case the tetrazole compound optionally obtained in this way is obtained from the salt contained in the reaction mixture by acidifies with a dilute acid such as 2N hydrochloric acid or 2N sulfuric acid.

In the reactions described above, any reactive groups present, such as carboxy, amino or alkylamino groups, can be protected during the reaction by customary protective groups, which are split off again after the reaction.

For example, the trimethylsilyl, methyl, ethyl, tert-butyl, benzyl or tetrahydropyranyl group and comes as a protective radical for a carboxy group

as a protective radical for an amino or alkylamino group, the acetyl, trifluoroacetyl, benzoyl, ethoxycarbonyl, tert.but-oxycarbonyl, benzyloxycarbonyl, benzyl, methoxybenzyl or 2, 4-dimethoxybenzyl group and additionally for the amino group Phthalyl group into consideration.

The subsequent subsequent splitting off of a protective residue used takes place, for example, hydrolytically in an aqueous solvent, e.g. in water, isopropanol / water, tetrahydrofuran / water or dioxane / water, in the presence of an acid such as trifluoroacetic acid, hydrochloric acid or sulfuric acid or in the presence of an alkali base such as lithium hydroxide, sodium hydroxide or potassium hydroxide or by means of ether cleavage, e.g. in the presence of iodotrimethylsilane, at temperatures between 0 and 100 ° C, preferably at temperatures between 10 and 50 ° C.

However, a benzyl, methoxybenzyl or benzyloxycarbonyl radical is split off, for example by hydrogenolysis, for example using hydrogen in the presence of a catalyst such as palladium / carbon in a solvent such as methanol, ethanol, ethyl acetate, dimethylformamide, dimethylformamide / acetone or glacial acetic acid, if appropriate with addition an acid such as hydrochloric acid at temperatures between 0 and 50 ° C, preferably however at room temperature and at a hydrogen pressure of 1 to 7 bar, but preferably from 3 to 5 bar.

A methoxybenzyl group can also be split off in the presence of an oxidizing agent such as cerium (IV) ammonium nitrate in a solvent such as methylene chloride, acetonitrile or acetonitrile / water at temperatures between 0 and 50 ° C., but preferably at room temperature.

However, a 2,4-dimethoxybenzyl radical is preferably cleaved in trifluoroacetic acid in the presence of anisole.

A tert-butyl or tert-butyloxycarbonyl radical is preferably cleaved off by treatment with an acid such as trifluoroacetic acid or hydrochloric acid, optionally using a solvent such as methylene chloride, dioxane or ether.

A phthalyl radical is preferably cleaved in the presence of hydrazine or a primary amine such as methylamine, ethylamine or n-butylamine in a solvent such as methanol, ethanol, isopropanol, toluene / water or dioxane at temperatures between 20 and 50 ° C.

An allyloxycarbonyl radical is split off by treatment with a catalytic amount of tetrakis (triphenylphosphine) palladium (O), preferably in a solvent such as tetrahydrofuran and preferably in the presence of an excess of a base such as morpholine or 1,3-dimedone at temperatures between 0 and 100 ° C, preferably at room temperature and under inert gas, or by treatment with a catalytic amount of tris (triphenylphosphine) rhodium (I) chloride in a solvent such as aqueous ethanol and optionally in the presence of a base such as 1,4-diazabicyclo - [2.2.2] octane at temperatures between 20 and 70 ° C. The compounds of general formulas II to X used as starting materials, some of which are known from the literature, are obtained by processes known from the literature, and their preparation is also described in the examples.

The chemistry of the compounds of general formula II is described, for example, by Jack Robinson in J. Chem. Soc. 1941, 744, the benzimidazoles by Katritzky and Rees in Comprehensive Heterocyclic Chemistry, Oxford, Pergamon Press, 1984, by Schaumann in Hetarene III, Methods of Organic Chemistry (Houben-Weyl), 4th edition, published by Thieme, Stuttgart 1993 ,

For example, a compound of the general formula II is obtained by acylation of a corresponding o-diamino compound with a corresponding reactive acyl derivative,

a compound of the general formulas III, IV, VI, VIII and IX by cyclization of a corresponding substituted compound according to process a) and, if necessary, subsequent conversion of a cyano compound thus obtained into the desired starting compound by known methods.

Furthermore, the compounds of general formula I obtained can be separated into their enantiomers and / or diastereomers.

For example, the compounds of general formula I obtained which occur in racemates can be converted into their optical antipodes and by known methods (see Allinger NL and Eliel EL in "Topics in Stereochemistry", Vol. 6, Wiley Interscience, 1971) Separate compounds of the general formula I with at least 2 asymmetric carbon atoms into their diastereomers on the basis of their physicochemical differences by methods known per se, for example by chromatography and / or fractional crystallization, which, if they occur in racemic form, finally, as mentioned above, can be separated into the enantiomers.

The separation of enantiomers is preferably carried out by column separation on chiral phases or by recrystallization from an optically active solvent or by reaction with a salt or derivative such as e.g. Optically active substance which forms esters or amides, in particular acids and their activated derivatives or alcohols, and separation of the diastereomeric salt mixture or derivative thus obtained, e.g. due to different solubilities, it being possible for the free antipodes to be released from the pure diastereomeric salts or derivatives by the action of suitable agents. Particularly common, optically active acids are e.g. the D and L forms of tartaric acid or dibenzoyltartaric acid, di-o-tolyltartaric acid, malic acid, mandelic acid, camphorsulfonic acid, glutamic acid, aspartic acid or quinic acid. Suitable optically active alcohols are, for example, (+) - or (-) menthol, and optically active acyl radicals in amides are, for example, the (+) - or (-) - menthyloxycarbonyl radicals.

Furthermore, the compounds of the formula I obtained can be converted into their salts, in particular for pharmaceutical use into their physiologically tolerable salts with inorganic or organic acids. Examples of suitable acids for this are hydrochloric acid, hydrobromic acid, sulfuric acid, methanesulfonic acid, phosphoric acid, fumaric acid, succinic acid, lactic acid, citric acid, tartaric acid or maleic acid.

In addition, the new compounds of formula I thus obtained, if they contain a carboxy group, can, if desired, subsequently be converted into their salts with inorganic or organic bases, in particular for their pharmaceutical use into their physiologically tolerable salts. The bases here are, for example, sodium hydroxide, ca lium hydroxide, cyclohexylamine, ethanolamine, diethanolamine and triethanolamine.

As already mentioned at the beginning, the new compounds of the general formula I and their salts have valuable properties. Thus, the compounds of general formula I, in which R _{c represents} a cyano group, are valuable intermediates for the preparation of the other compounds of general formula I, and the compounds of general formula I, in which R _{c represents} one of the amidino groups mentioned at the outset, and Their tautomers, their stereoisomers and their physiologically tolerable salts have valuable pharmacological properties, in particular an antithrombotic effect, which is preferably based on an action influencing thrombin or factor Xa, for example on a thrombin-inhibiting or factor Xa-inhibiting action, on one the aPTT time prolonging effect and on an inhibitory effect on related serine proteases such as. B. trypsin, urokinase factor VIIa, factor IX, factor XI and factor XII.

For example, the connections

A = 2- (4-amidinophenylaminomethyl) -1-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole dihydrochloride,

B = (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- [(R, S) -2-methyl-pyrrolidinocarbonyl] ethyl] - benzimidazole- dihydrochloride and

C = (2) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole dihydrochloride

examined for their effect on the aPTT time extension as follows: Material: -plasma, from human citrate blood,

-PTT reagent, Boehringer Mannheim (524298),

Calcium solution (0.025 mol / 1), Behring Werke, Marburg

(ORH 056/57), -Diethylbarbituratacetat-Puffer, Behring Werke, Marburg (ORWH 60/61), -Biomatic BIO Coagulometer, Desaga, Wiesloch.

Execution :

The aPTT time was determined using a Biomatic BIO coagulometer from Desaga.

The test substance was placed in the test vessels prescribed by the manufacturer with 0.1 ml of human citrate plasma and 0.1 ml of PTT reagent. The mixture was incubated at 37 ° C for three minutes. The coagulation reaction was started by adding 0.1 ml of calcium solution. Depending on the device, the calcium solution is measured and the time taken for the batch to clot is measured. Batches in which 0.1 ml of DBA buffer were added served as a control.

According to the definition, the effective substance concentration was determined via a dose-response curve, at which the aPTT time was doubled compared to the control.

The following table contains the values found:

The compounds prepared according to the invention are well tolerated, since no toxic side effects could be observed at therapeutic doses. speaking prodrugs, for example the compounds of Examples 1 (6), 2, 3 (2) and 3 (5), have good oral absorption.

Due to their pharmacological properties, the new compounds and their physiologically tolerable salts are suitable for the prevention and treatment of venous and arterial thrombotic diseases, such as the treatment of deep vein thrombosis, the prevention of reocclusions after bypass surgery or angioplasty (PT ( C) A), as well as occlusion in peripheral arterial diseases such as pulmonary embolism, disseminated intravascular coagulation, prophylaxis of coronary thrombosis, prophylaxis of stroke and prevention of occlusion of shunts. In addition, the compounds according to the invention are for antithrombotic support in thrombolytic treatment, such as, for example, with rt-PA or streptokinase, for preventing long-term restosis after PT (C) A, for preventing metastasis and the growth of coagulation-dependent tumors and of fibrin-dependent inflammatory processes , e.g. in the treatment of pulmonary fibrosis.

The dosage required to achieve a corresponding effect is expediently 0.1 to 30 mg / kg, preferably 0.3 to 10 mg / kg for intravenous administration and 0.1 to 50 mg / kg, preferably 0.3 to for oral administration 30 mg / kg, 1 to 4 times a day. To this end, the compounds of the formula I prepared according to the invention, optionally in combination with other active substances, together with one or more inert customary carriers and / or diluents, for example with corn starch, lactose, cane sugar, microcrystalline cellulose, magnesium stearate, polyvinylpyrrolidone, citric acid, tartaric acid, Water, water / ethanol, water / glycerin, water / sorbitol, water / polyethylene glycol, propylene glycol, cetylstearyl alcohol, carboxymethyl cellulose or fatty substances such as hard fat or their suitable mixtures, in conventional pharmaceutical preparations such as tablets, Work in coated tablets, capsules, powder, suspensions or suppositories.

The following examples are intended to explain the invention in more detail:

Ren s i el 1

(R) -2- [4- [N- (4-Methylphenylcarbonyl) amidino] phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (pyrro-

1 id nocarbonyl-ethyl1-benzimidazole a. (R) -5- (4-chloro-3-nitro-phenyl) -5-methyl-imidazolidine

2,4-dione

10.0 g (4.45 mmol) (R) -5- (4-chlorophenyl) -5-methyl-imidazolidin-2, 4-dione are added in portions to 50 ml of fuming nitric acid at -25 to -35 ° C. After 45 minutes at -25 to -20 ° C, the reaction mixture is poured onto ice water. The crystalline product is filtered off, washed with water and dried. Yield: 10.5 g (100% of theory), melting point: 173-178 ° CR _f value: 0.30 (silica gel; cyclohexane / ethyl acetate = 1: 1)

, (R) -2-Aττπ.no-2- (4-chloro-3-πitro-phenyl) propionic acid

10.5 g (0.044 mol) of (R) -5- (4-chloro-3-nitro-phenyl) -5-methylimidazolidin-2, 4-dione are refluxed in 200 ml of dioxane and 700 ml of 6N hydrochloric acid for 5 days , The solution is evaporated, the residue is taken up in water and extracted with ethyl acetate. The aqueous phase is evaporated, toluene is added and the mixture is evaporated to dryness. The residue is triturated with ether, suction filtered and dried. Yield: 6.8 g (63% of theory),

R _f value: 0.24 (reversed phase RP8, 5% saline / methanol = 1: 1)

c. (R) -2-tert. Butyloxycarbonylamino-2- (4-chloro-3-nitro-phenyl) propionic acid

72.5 g (0.296 mol) of (R) -2-amino-2- (4-chloro-3-nitro-phenyl) propionic acid are dissolved in 850 ml of dioxane and 200 ml of water and after addition of 108.7 ml (0.78 mol) of triethylamine and 136 g (0.623 mol) of di-tert-butyl dicarbonate were stirred at room temperature for 18 hours. After adding 800 ml IN sodium hydroxide solution, the solution is stirred for 30 minutes and then 3 times with 500 ml each Ether extracted. The aqueous phase is adjusted to pH 7 with 1N hydrochloric acid and then to pH 4 with 5% citric acid. After 4-fold extraction with 500 ml each of ethyl acetate, the combined organic phases are washed with water,, after drying over magnesium sulfate, suction filtered and evaporated. Yield: 86.8 g (85% of theory), R _f value: 0.3 (silica gel; methylene chloride / methanol = 4: 1 + 1%

Ammonia) C ₁₄ H ₁₇ C1N ₂ 0 ₆ (344.7) mass spectrum: (MH) ^" = 343

d. (R) -2-tert. Butyloxycarbonylamino-2- (4-methylamino-3-nitrophenyl) propionic acid

96 g (0.278 mol) of (R) -2-tert-butyloxycarbonylamino-2- (4-chloro-3-nitro-phenyl) propionic acid and 440 ml of methylamine solution

(40% solution in water) are heated in a pressure vessel at 90 ° C for seven hours. After cooling, the reaction solution is adjusted to pH 3.5 with ice cooling by adding glacial acetic acid and extracted with ethyl acetate. After evaporation of the solvent, the remaining residue is washed with ether and dried.

Yield: 70 g (74% of theory), R _f value: 0.30 (silica gel; methylene chloride / ethanol = 19: 1 +

1% glacial acetic acid) C ₁₅ H ₂₁ N ₃ 0 ₆ (339.3) Mass spectrum: (MH) ^" = 338

e. (R) -2- (4-methylamino-3-nitro-phenyl) -2-tert. butyloxycar- bonylaττti o-1 -pyrrolidino-propanone

50 g (0.147 mol) of (R) -2-tert-butyloxycarbonylamino-2- (4-methylamino-3-nitro-phenyl) propionic acid are dissolved in 275 ml of dimethylformamide and, after adding 47.5 g (0.147 mol), 0 - (Benzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium tetrafluoroborate, 24.5 g (0.334 mol) pyrrolidine and 30 ml (0.273 mol) N-methylmorpholine were stirred for 20 hours at room temperature. The solution is poured onto ice water and acidified with citric acid (pH 5-6). The precipitate formed is filtered off, washed with water and dried. Yield: 45.5 g (79% of theory), R _f value: 0.6 (silica gel; petroleum ether / ethyl acetate = 1: 1)

f. (R) -2- (4-methylamino-3-aminophenyl) -2-tert-butyloxycarbonyl mino-1-pyrrole idi no-propanone

25.5 g (65 mmol) of (R) -2- (4-methylamino-3-nitro-phenyl) -2-tert. - Butyloxycarbonylamino-1-pyrrolidino-propanone are dissolved in 650 ml of methanol and, after addition of 4.0 g of palladium on activated carbon (20%), hydrogenated for 2 hours at room temperature. The catalyst is then filtered off and evaporated. Yield: 21.4 g (91% of theory),

R _f value: 0.31 (silica gel; ethyl acetate + 1% ammonia)

G. (R) -2- [4-Methylamino-3- (4-cyanophenylaminomethylcarbonylamino) phenyl] -2-tert-butyloxycarbonylamino-1-pyrrolidino-ropanone

Prepared analogously to example le from (R) -2- (4-methylamino-

3-amino-phenyl) -2-tert. Butyloxycarbonylamino-1-pyrrolidino-propanone, O- (benzotriazol-1-yl) -N, N, N ', N' -tetramethyluronium tetrafluoroborate, 4-cyano-phenylglycine and N -Methyl morpholine in dimethylformamide. Yield: 100% of theory, R _f value: 0.47 (silica gel; ethyl acetate)

H. (R) -2- (4-cyanophenylaminomethyl) -l-methyl-5- [1- (N-tert-butyloxycarbonylamino) -1- (pyrrolidinocarbonyl) ethyl] -benz-imidazo]

47.7 g (0.042 mol) of (R) -2- [4-methylamino-3- (4-cyanophenylamino-methylcarbonylamino) -phenyl] -2-tert. Butyloxycarbonylamino-1-pyrrolidino-propanone are refluxed in 300 ml of glacial acetic acid for 2 hours heated. The reaction mixture is poured onto ice water and concentrated with. Bring ammonia to pH 8. The precipitate formed is filtered off, washed with water and dried. Yield: 46 g (100% of theory), R _f value: 0.3 (silica gel; ethyl acetate + 1% ammonia)

i. (R) -2- (4-cyanophenylaminomethyl) -l-methyl-5- [1-amino-

1 - (pyrrp] ri d.i nocarbonyl) ethyll benzimidazole

25.1 g (50 mmol) of (R) -2- (4-cyanophenylaminomethyl) -1-methyl- 5- [1- (N-tert. Butyloxycarbonylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole are dissolved in 500 ml of 6N Hydrochloric acid dissolved at 35 ° C and stirred for one hour at this temperature. The solution is mixed with ice, made alkaline with ammonia and extracted with ethyl acetate. The combined organic extracts are dried and evaporated. Yield: 17.8 g (88% of theory),

R _f value: 0.5 (silica gel; methylene chloride / ethanol = 4: 1 + 1% ammonia)

k. (R) -2- (4-cyanophenylaminomethyl) -l-methyl-5- (1-ethoxycarbonylmultiylamino) -1- fpyrrole dinorarbonyl) ethyll -benzimi azole 4.2 g (10.44 mmol) (R) -2- ( 4-Cyanophenylaminomethyl) -1-methyl- 5- [1-amino-l- (pyrrolidinocarbonyl) ethyl] benzimidazole are dissolved in 100 ml acetone and with 2.3 g (16.65 mmol) potassium carbonate and 2.25 ml (20.2 mmol) Ethyl bromoacetate added. The suspension is heated to 60 ° C for 5 hours. After cooling, the reaction mixture is stirred into 400 ml of ice water, the precipitate formed is filtered off, washed with water and dried. The crude product is chromatographed on silica gel, eluting with methylene chloride / ethanol (19: 1 and 9: 1). The uniform fractions are combined and evaporated. Yield: 3.1 g (61% of theory), R _f value: 0.4 (silica gel; ethyl acetate / ethanol = 9: 1)

1. (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (1-ethoxycarbonylethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole hydrochloride

6.8 g (13.8 mmol) (R) -2- (4-cyanophenylaminomethyl) -1-methyl- 5- [1-ethoxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole are ethanolic in 400 ml saturated Hydrochloric acid dissolved and stirred for 23 hours at room temperature. The solvent is distilled off, the residue is dissolved in 200 ml of absolute ethanol and 20 g (0.21 mol) of ammonium carbonate are added. After 20 hours at room temperature, 100 ml of ethanol are added and, after stirring for a further 10 hours at room temperature, the mixture is filtered and evaporated to dryness. The residue is stirred in 200 ml of acetone, filtered off, washed with ether and dried. Yield: 7.6 g (100% of theory), R _f value: 0.61 (reversed phase RP8; 5% sodium chloride solution / -

Methanol = 3: 2) C ₂₇ H _3S N ₇ 0 ₃ x HC1 (505.64 / 542.09) mass spectrum: (M + H) ⁺ = 506

m. (R) -2- [4- [N- (4-Methylphenylcarbonyl) amidino] phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyll - benzimi azo]

A suspension of 0.7 g (1.2 mmol) of (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole dihydrochloride in 25 4.0 ml (28 mmol) of triethylamine and 0.8 g (3.0 mmol) of 4-methyl-4-nitrophenyl ester are added to ml of methylene chloride and the mixture is heated at 50 ° C. for 3.5 hours, a clear solution being formed. After cooling, it is washed with sodium bicarbonate solution, saline and water, dried over magnesium sulfate and evaporated. The crude product is purified on silica gel, eluting with ethyl acetate / ethanol (50: 1 and 9: 1). The uniform fractions are combined, evaporated, triturated with ether, suction filtered and dried. Yield: 0.5 g (66% of theory),

R _f value: 0.50 (silica gel; ethyl acetate / ethanol = 9: 1) C ₃₅ H ₄₁ N ₇ 0 ₄ (623.75) mass spectrum: (M + H) ⁺ = 624

(M + Na) ⁺ = 646

(MH) ^" = 622

The following compounds are obtained analogously to Example 1: (1) (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (isopropyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole acetate

Yield: 69% of theory,

R _f value: 0.2 (silica gel; methylene chloride / ethanol = 7: 3 +

1% glacial acetic acid) C ₂₈ H ₃₇ N ₇ 0 ₃ x CH ₃ COOH (519.65 / 579.70) Mass spectrum: (M + H) ⁺ = 520

(MH) ^" = 518

(2) (R) -2- [4- [N- (4-Fluorophenylcarbonyl) amidino] phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] - benzimidazole

Yield: 40% of theory,

R _£ value: 0.4 (silica gel; ethyl acetate / ethanol = 9: 1 +

1% ammonia) C ₃₄ H ₃₈ FN ₇ 0 ₄ (627.72) mass spectrum: (M + H) ⁺ = 628

(M + Na) ⁺ = 650

(MH) ^" = 626

(3) (R) -2- [4- [N- (4-trifluoroethylphenylcarbonyl) amidino] phenylaminomethyl] 1-methyl-5- [1- (ethoxycarbonylmethylamino) 1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 47% of theory,

R _f value: 0.53 (silica gel; methylene chloride / methanol / concentrated ammonia = 9: 0.9: 0.1) C ₃₅ H ₃₈ F ₃ N ₇ 0 ₄ (677.73) mass spectrum: (M + H) ⁺ = 678

(M + Na) ⁺ = 700

(MH) ^" = 676

(4) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (tetrazol-5-yl-methylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole (5) 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole dihydrochloride

Yield: 94% of theory,

R _f value: 0.2 (reversed phase RP8; 5% saline / methanol

= 2: 3) C ₂₇ H ₃₃ N ₇ 0 ₃ X 2 HC1 (503. 6/576. 51) mass spectrum: (M + H) ⁺ = 504

(M-H + HC1) ^" = 538/540 (Cl)

(6) 2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolo-carbonyl) ethyl] benzimidazole

Yield: 71% of theory,

R _f value: 0.3 (silica gel; ethyl acetate / ethanol = 9: 1)

C ₃₄ H ₃₇ N ₇ 0 ₄ (607.72)

Mass spectrum: (M + H) ⁺ = 608

(M + Na) ⁺ = 630

(MH) ^" = 606

(7) (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- [(R, S) -1-methylpyrrolidinocarbonyl] ethyl] benzimidazole dihydrochloride (Mixture of diastereomers) yield: 88% of theory,

R _f value: 0.3 (reversed phase RP8; 5% saline / methanol

= 3: 2) C ₂₈ H ₃₇ N ₇ 0 ₃ X 2 HC1 (519.65 / 592.56) mass spectrum: (M + H) ⁺ = 520

(M + Cl) ^" = 554/6 (Cl)

(8) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (3-ethoxycarbonylpropylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 19% of theory,

R _f value: 0.44 (silica gel; methylene chloride / methanol = 4: 1 + 1%

Glacial acetic acid) C ₃₆ H ₄₃ N ₇ 0 ₄ (637.79) Mass spectrum: (M + H) ⁺ = 638

(MH) ^" = 636

(9) (R) -2- [4- (Nn-hexyloxycarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (n-propyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole Yield: 70% the theory

R _f value: 0.37 (silica gel; ethyl acetate / ethanol = 9: 1) C ₃₅ H ₄₉ N ₇ 0 ₅ (647.82) mass spectrum: (M + Na) ⁺ = 670

(MH) ^" = 646

Example 2.

(R) -2- [4- (N-Phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (n-butyloxycarbonylmethylamino) -1- (pyrrolidino-πarbonyl.) -Ethyll -benzimi azole

A solution of 0.3 g (0.53 mmol) of (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole 0.1 g (0.46 mmol) of 2, 8, 9-trimethyl-l-phospha-2, 5, 8, 9-tetraazabicyclo [3.3.3] undecane is added to 5 ml of n-butanol and the mixture is stirred at room temperature for 1 hour. The reaction mixture is purified on silica gel, with ethyl acetate / ethanol / conc. Ammonia (50: 0.95: 0.05 and 20: 0.95: 0.05) is eluted. The uniform fractions are combined and evaporated. Yield: 0.19 g (57% of theory, R _f value: 0.45 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₆ H ₄₃ N ₇ 0 ₄ (637.78) mass spectrum: (M + H) ⁺ = 638

(M + Na) ⁺ = 660

(MH) ^" = 636

The following compounds are obtained analogously to Example 2: (1) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (isobutyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 16% of theory,

R _f value: 0.48 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₆ H ₄₃ N ₇ 0 ₄ (637.78) mass spectrum: (M + H) ⁺ = 638

(M + Na) ⁺ = 660

(MH) ^" = 636

(2) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (2-methoxyethyloxycarbonylmethylamino) -

1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 43% of theory,

R _f value: 0.31 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₅ H ₄₁ N ₇ 0 ₅ (639.76) mass spectrum: (M + H) ⁺ = 640

(MH) ^" = 638

(3) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (2-dimethylaminoethyloxycarbonylmethylamino) - 1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 23% of theory,

R _f value: 0.26 (silica gel; methylene chloride / methanol / ammonia =

9: 0.9: 0.1) C ₃₆ H ₄₄ N ₈ 0 ₄ (652.8) Mass spectrum: (M + H) ⁺ = 651

(MH) ^" = 653

(4) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (2- (2-methylphenyl) ethyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] -benzimidazole yield: 23% of theory,

R _f value: 0.52 (silica gel; ethyl acetate / ethanol / ammonia =

9: 0.95: 0.05) C ₄₁ H ₄₅ N ₇ 0 ₄ (699.86)

Mass spectrum: (M + H) ⁺ = 700

(M + Na) ⁺ = 722

(MH) ^" = 698

(5) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (cyclohexyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole Yield: 34% of theory , R _f value: 0.49 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₈ H ₄₇ N ₇ 0 ₄ (663.83) mass spectrum: (M + H) ⁺ = 664

(M + Na) ⁺ = 686

(MH) ^" = 662

Example 3

(R) -2- [4- (N-Phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (isopropyloxycarbonylmethylamino) -1- (2,5-dihydro-yrrolocarbonylethyll -benzimidazole.

To a solution of 0.5 g (0.82 mmol) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolocarbonyl) -ethyl] -benzimidazole in 12.3 ml of isopropanol, 2.1 ml of conc. Added dropwise sulfuric acid. After 4 hours at 85 ° C, the solution is cooled and poured onto 250 ml of ice water. By adding conc. Ammonia, the pH is adjusted to 8.5. The precipitate formed is filtered off, dried and purified on silica gel, eluting with methylene chloride + 2% methanol + 0.01% ammonia. The uniform fractions are combined and evaporated, the residue is triturated with ether, filtered off and dried. Yield: 0.19 g (37% of theory), R _f value: 0.46 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₅ H ₃₉ N ₇ 0 ₄ (621.75) Mass spectrum: (M + H) ⁺ = 622

(M + Na) ⁺ = 644 (MH) ^" = 620

The following compounds are obtained analogously to Example 3:

(1) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (n-propyloxycarbonylmethylamino) -1- (2,5-di-hydropyrrolocarbonyl) ethyl] benzimidazole

Yield: 33% of theory,

R _f value: 0.46 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₅ H ₃₉ N ₇ 0 ₄ (621.75) mass spectrum: (M + H) ⁺ = 622

(M + Na) ⁺ = 644 (MH) ^" = 620

(2) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (n-propyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 36% of theory,

R _f value: 0.45 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₃₅ H _4f N ₇ 0 ₄ (623.76) mass spectrum: (M + H) ⁺ = 624

(M + Na) ⁺ = 646

(MH) ^" = 622

(3) (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (n-butyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole dihydrochloride

Yield: 8% of theory,

R _f value: 0.44 (silica gel; methylene chloride / methanol = 4: 1 + 1%

Ammonia) C ₂₉ H ₃₉ N ₇ 0 ₃ x 2 HC1 (533.69 / 606.6) mass spectrum: (M + H) ⁺ = 534

(MH) ^" = 532 (4) (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (n-propyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole sulfate

Yield: 7% of theory,

R _f value: 0.36 (silica gel; methylene chloride / methanol = 4: 1 + 1%

Ammonia) C ₂₈ H ₃₇ N ₇ 0 ₃ XH ₂ S0 ₄ (519.65 / 617.7) mass spectrum: (M + H) ⁺ = 520

(5) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (cyclohexyloxycarbonylmethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole

Yield: 22% of theory,

R _f value: 0.60 (silica gel; ethyl acetate / ethanol = 9: 1 + 1% ammonia) C ₃₈ H ₄₃ N ₇ 0 ₄ (661.81) mass spectrum: (M + H) ⁺ = 662

(M + Na) ⁺ = 684

(MH) ^" = 660

(6) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (3- (isopropyloxycarbonyl) propylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

(7) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (3- (n-propyloxycarbonyl) propylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Example 4

(R) -2- (4-amidinophenylaminomethyl) - 1-methyl-5 - [1- (tetrazole-5-yl-methylamino) -1 - (pyrrole di carbonyl) ethyl 1 -benz mi ol a. 4 - (5-Methyl-1,2,4 -oxadiazol-3-yl) -phenylamino-acetic acid, ethyl ester Prepared analogously to Example 1k from 4- (5-methyl-1,2,4,4-oxadiazol-3-yl) aniline and ethyl bromoacetate in N-ethyldiisopropylamine.

Yield: 78% of theory,

R _f value: 0.60 (silica gel; ethyl acetate / petroleum ether = 1: 1)

b. 4- (5-Methyl-l, 2,4-oxadiazol-3-yl) -phenyl-N-tert. Butyloxy-carbonyl mlno-acetic acid ethyl ester

Prepared analogously to Example 1c from 4- (5-methyl-1,2,4,4-oxadiazol-3-yl) -phenylamino-acetic acid ethyl ester and di-tert. Butyl-dicarbonate / N-ethyl-diisopropylamine in dioxane.

Yield: 63% of theory,

R _f value: 0.48 (silica gel; ethyl acetate / cyclohexane = 1: 2)

c. 4- (5-methyl-1, 2, 4-oxadiazol-3-yl) phenyl-N-tert. Butyloxyz. carbonyl-aminoacetic

A solution of 3.5 g (9.7 mmol) of 4- (5-methyl-1,2,4-oxadiazol-3-yl) -phenyl-N-tert. Butyloxycarbonylamino-acetic acid ethyl ester in 10 ml of tetrahydrofuran and 4 ml of methanol is mixed with 9.7 ml

IN sodium hydroxide solution (9.7 mmol) and stirred for 3 hours at room temperature. The reaction mixture is evaporated to half its volume and water is added. The pH is adjusted to 4-5 by adding glacial acetic acid, the precipitate formed is filtered off, washed with water and dried.

Yield: 2.8 g (87% of theory),

R _f value: 0.5 (reversed phase RP8; 5% saline / methanol = 1: 3)

d. (R) -2- [4- (5-Methyl-l, 2,4-oxadiazol-3-yl) -phenyl-N-tert. Butyloxycarbonyl-aminomethyl] -l-methyl-5- [2-tert .butyloxycarbonylamino-1 - (pyrroli inocarbonyl) ethyll -benzimidazole

Prepared analogously to example lg / h from (R) -2- (4-methylmino-

3-amino-phenyl) -2-tert. Butyloxycarbonylamino-1-pyrrolidino-propanone, 4- (5-methyl-1,2,4,4-oxadiazol-3-yl) -phenyl-N-tert. butyloxycarbonylminoacetic acid and carbonyldiimidazole in tetrahydrofuran and subsequent treatment with glacial acetic acid. Yield: 47% of theory,

R _f value: 0.46 (silica gel; ethyl acetate)

e. (R) - 2- [4- (5-Methyl-1,2,4,4-oxadiazol-3-yl) phenylaminomethyl] -l-methyl-5- [1-amino-1- (pyrrolidinocarbonyl) ethyl] - benzimidazole

Prepared analogously to example li from (R) -2- [4- (5-methyl-1,2,4-oxadiazol-3-yl) phenyl-N-tert-butyloxycarbonylaminomethyl] -1-methyl-5- [ 2-tert. Butyloxycarbonyl-amino-1- (pyrrolidinocarbonyl) ethyl] benzimidazole and 6N hydrochloric acid.

Yield: 91% of theory,

R _f value: 0.44 (silica gel; methylene chloride / methanol / ammonia =

9: 0.9: 0.1)

f. (R) -2- [4- (5-Methyl-1,2,4,4-oxadiazol-3-yl) phenylaminomethyl] -l-methyl-5- [1-cyanomethylamino-1- (pyrrolidinocarbonyl) ethyl benzimide a ol

Prepared analogously to Example lk from (R) - 2- [4- (5-methyl-1,2,4-oxadiazol-3-yl) -phenylaminomethyl] -l-methyl-5- [1-amino-l- (pyrrolidinocarbonyl ) -ethyl] -benzimidazole and bromoacetonitrile / potassium carbonate in acetone.

Yield: 72% of theory,

R _f value: 0.54 (silica gel; ethyl acetate / ethanol = 9: 1 + 1%

Ammonia) C ₂₇ H ₃₀ N _B 0 _2. (498.59)

Mass spectrum: (M + H) ⁺ = 499

(MH) ^" = 497

(M + Na) ⁺ = 521

G. (R) -2- [4- (5-Methyl-l, 2,4-oxadiazol-3-yl) phenylaminomethyl] -l-methyl-5- [1- (tetrazol-5-yl-methylamino) -1 - (pyrrolidinocarbony) ethyll benzimide ol

1.1 g (2.2 mmol) (R) - 2- [4- (5-methyl-1,2,4,4-oxadiazol-3-yl) phenylaminomethyl] -l-methyl-5- [1-cyanomethylamino-1- ( pyrrolidinocarbonyl) ethyl] benzimidazole are suspended in 20 ml of toluene and 60 ml of dioxane, and 2.2 g (6.6 mmol) of tributyltin azide are added. The reaction mixture is on for 6 hours Heated to 130 ° C. After evaporation of the solvent, the residue is triturated with petroleum ether, filtered, washed with petroleum ether and dried. The crude product is purified on silica gel, eluting with methylene chloride / methanol 20: 1 and 9: 1. The uniform fractions are combined and evaporated.

Yield: 0.7 g (59% of theory)

R _f value: 0.33 (silica gel; methylene chloride (methanol = 9: 1) C ₂₇ H _3α N _αι 0 ₂ (541.6) mass spectrum: (MH) ^" = 540

(M + Na) ⁺ = 564

H. (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (tetrazole- 5-yl-methylami.no) -1- (pyrrolidinocarbonyl.) -Ethyll -benzimi azole Prepared analogously to Example lh from ( R) - 2- [4- (5-methyl-1,2,4,4-oxadiazol-3-yl) phenylaminomethyl] -l-methyl-5- [1- (tetrazol-5-yl-methylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole and hydrogen / palladium (20% on activated carbon) in ethanol / glacial acetic acid.

Yield: 63% of theory,

R _f value: 0.35 (reversed phase RP8; 5% saline / methanol = 4: 3)

^C ₂₅ ^H ₃₁ ^N ₁₁ ⁰ (501.6)

Mass spectrum: (M + H) ⁺ = 502

(MH) ^" = 500

Example 5

2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethyloxymethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole acetate a. 2- (4-chlorophenyl) -3-hydroxy-2-methyl-propionic acid methyl ester

35 ml of a 1.6 molar solution of n-butyllithium in hexane (61 mmol) are added dropwise to a solution of 8.1 ml of diisopropylamine (85 mmol) in 20 ml of tetrahydrofuran at -78 ° C. A solution of 10.0 g (50 mmol) of 2- (4-chloro- phenyl) propionic acid methyl ester in 30 ml of tetrahydrofuran added dropwise at -78 ° C. Gaseous formaldehyde is introduced into the reaction mixture at -20 ° C. for 30 minutes. After adding 5% citric acid and glacial acetic acid, it is extracted with ethyl acetate. The organic phases are washed with 1N sulfuric acid, water, saturated sodium bicarbonate solution and brine and dried over magnesium sulfate. The crude product is purified on silica gel, eluting with cyclohexane / ethyl acetate (19: 1; 9: 1; 4: 1; 1: 1 and 0: 1). The uniform fractions are combined and evaporated. Yield: 9.7 g of yellow oil (84% of theory), R _f value: 0.25 (silica gel; petroleum ether / ethyl acetate = 4: 1)

b. ^■ ?. - (4-Chlorophenyl) -3-hydroxy-2-methyl-propionic acid Prepared analogously to Example 8 from methyl 2- (4-chlorophenyl) -3-hydroxy-2-methyl-propionate and sodium hydroxide solution in ethanol.

Yield: 83% of theory,

R _f value: 0.55 (silica gel; ethyl acetate / cyclohexane = 2: 1 + 1%

glacial)

c. 2- (4-chloro-nitro-phenyl.) -2-methyl-3-nitrooxy-propionic acid Prepared analogously to example la from 2- (4-chlorophenyl) -3-hy-

, droxy-2-methyl-propionic acid and nitric acid. Yield: 90% of theory, melting point: 129-132 ° CC ₁₀ H ₉ ClN ₂ O ₇ (304.64)

d. 2- (4-Chloro-3-nitro-pheny) -2-methyl-3-hydroxy-propionic acid Prepared analogously to example li from 2- (4-chloro-3-nitro-phenyl) -3-nitrooxy-2-methyl -propionic acid and 6N hydrochloric acid in dioxane. Yield: 98% of theory,

C ₁₀ H ₁₀ ClNO ₅ (259.65)

Mass spectrum: (MH) ^" = 258/60 (Cl) e. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-hyoxypropionic acid

Prepared analogously to Example le from 2- (4-Ch.lor-3-nitro-ph.enyl) -3-hydroxy-2-methyl-propionic acid and N-methyl-benzylamine. Yield: 81% of theory,

C ₁₈ H ₂₀ C1N ₂ 0 ₅ (344.37) mass spectrum: M ⁺ = 344

f. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-hyoxy-1-pyrrodin-1-yl-propan-1-one

Prepared analogously to Example le from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -3-hydroxy-2-methyl-propionic acid and pyrrolidine.

Yield: 96% of theory, C ₂₂ H ₂₇ N ₃ 0 ₄ (397.48) mass spectrum: M ⁺ = 398

(M + Na) ⁺ = 420

G. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-eth-oxycarbonylmethyloxy-1-pyrrole idino-propane-l. -one

A solution of 8.0 g (20 mmol) of 2- [4- (N-benzyl-methylamino) -

3-nitro-phenyl] -2-methyl-3-hydroxy-l-pyrrolidino-propan-l-one and 5 ml (48 mmol) of diazoacetic ester in 50 ml of methylene chloride are mixed with 2.0 ml of boron trifluoride-diethyl ether complex (16 mmol ) added and heated under reflux for 14 hours. After cooling, the reaction solution is stirred into ice water and the organic phase is separated off. The aqueous phase is extracted three times with methylene chloride, the combined organic phases are washed with brine, dried over sodium sulfate and evaporated. The residue is dissolved in ethyl acetate and purified on silica gel, initially with petroleum ether, later with petroleum ether / ethyl acetate (1: 1). The uniform fractions are combined and evaporated. Yield: 2.5 g (26% of theory), R _f value: 0.6 (silica gel; ethyl acetate) C ₂₆ H ₃₃ N ₃ 0 ₆ (483.57) Mass spectrum: (M + H) ⁺ = 484

H. 2- (4-methylamino-3-aminophenyl) -2-methyl-3-ethoxycarbonylethyloxy-1-pyrrole idino-propan-l-one

Prepared analogously to Example lf from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-ethoxymethyloxy-1-pyrrolidin-1-yl-propan-l-one and hydrogen / palladium on activated carbon. Yield: 81% of theory, R _f value: 0.40 (silica gel; methylene chloride / ethanol = 19: 1)

i. 2- (4-Cyanophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonyl-methyl oxymethyl) -1 - (pyrrole i dinocarbonyl) -ethyl-benzi idazole Prepared analogously to Example lg / h from 2- (4-methylamino- 3-aminophenyl) -2-methyl-3-ethoxycarbonylmethyloxy-1-pyrrolidino-propan-1-one, 4-cyano-phenylglycine / O- (benzotriazol-1-yl) - N, N, N ', N'-tetramethyluronium tetrafluoroborate and subsequent treatment with glacial acetic acid. Yield: 77% of theory,

R _f value: 0.40 (silica gel; methylene chloride / ethanol = 19: 1) C ₂₈ H ₃₃ N _s 0 ₄ (503.61) mass spectrum: (M + H) ⁺ = 504

(M + Na) ⁺ = 526

k. 2 - (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethyloxymethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole acetate

Prepared analogously to Example 11 from 2- (4-cyanophenylamino-methyl) -l-methyl-5- [1- (ethoxycarbonylmethyloxymethyl) -1- (pyrrolidinocarbonyl) -ethyl] -benzimidazole and hydrochloric acid / ammonium carbonate in ethanol. Yield: 64% of theory, R _f value: 0.25 (silica gel; methylene chloride / ethanol = 4: 1 + 1%

Glacial acetic acid) C ₂₈ H ₃₆ N ₆ 0 ₄ x CH ₃ C00H (520.63 / 580.69) mass spectrum: (M + H) ⁺ = 521 Example - 6.

2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (1H-tetrazole-5-yl-methyl) -1- (pyrrolidinocarbonyl) -ethyl] -benzimidazole-hydrochlori a. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-methanesulfonyl xy-1-pyrrole idi o-propan-l -one

A solution of 1.2 g (3.0 mmol) of 2- [4- (N-benzyl-methylamino) - 3 -nitro-phenyl] -2-methyl-3-hydroxy-1-pyrrolidino-propan-l-one in 20 ml of tetrahydrofuran is at room temperature with 1.3 ml

(9.3 mmol) triethylamine added. Then 0.27 ml (3.5 mmol) of methanesulfonyl chloride are added dropwise at 2-5 ° C. After 2 hours at room temperature, the precipitate formed is suction filtered and the filtrate is evaporated. The raw product is further implemented without purification. Yield: 1.4 g (98% of theory).

b. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-cyano-1-pyrrole 1 din-propan-1-one

A solution of 8.2 g (17 mmol) of 2- [4- (N-benzyl-methylamino) -

3-nitro-phenyl] -2-methyl-3-methanesulfonyloxy-1-pyrrolidino-propan-1-one in 125 ml of dimethylformamide are mixed with 1.8 g (27 mmol) of potassium cyanide and heated to 100 ° C. for 2 hours. After cooling, the reaction solution is stirred into ice water and extracted 3 times with ethyl acetate. The combined organic phases are washed with brine and dried over sodium sulfate. The crude product is dissolved in methylene chloride and purified on silica gel, eluting initially with methylene chloride, later with methylene chloride / ethanol (50: 1 and 25: 1). The uniform fractions are combined and evaporated. Yield: 5.0 g (72% of theory)

R _f value: 0.45 (silica gel; methylene chloride / ethanol = 19: 1) C ₂₃ H ₂₆ N ₄ 0 ₃ (406.49) mass spectrum: M ⁺ = 406

(M + Na) ⁺ = 429 c. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3- (1H-f-ehrazole -5-yl) -1-pyrrole-idino-propane -one

Prepared analogously to Example 4g from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-cyano-l-pyrrolidino-propan-l-one and tributyltin azide.

Yield: 37% of theory,

R _f value: 0.55 (silica gel; methylene chloride / ethanol = 9: 1) C ₂₃ H ₂₇ N ₇ 0 ₃ (449.52) mass spectrum: (M + Na) ⁺ = 472

(MH) ^" = 448

d. 2- [4- (N-Methylamino) -3-aminophenyl] -2-methyl-3- (1H-tetrazol-5-yl) -1-pyrrolidino-propan-l-one

Prepared analogously to Example 1f from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3- (1H-tetrazol-5-yl) -1-pyrrolidino-propan-1 -on and hydrogen / palladium on activated carbon. Yield: 48% of theory,

R _f value: 0.3 (silica gel; methylene chloride / ethanol = 9: 1) C ₁₆ H ₂₃ N ₇ 0 (329.41) mass spectrum: (M + H) ⁺ = 330

(MH) ^" = 328

e. 2- (4-Cyanophenylaminomethyl) -l-methyl-5- [1- (1H-tetrazol-5-ylmethyl) -1- (pyrrole idi.nocarbonyl) -ethyll -benzimide zol Prepared analogously to Example lg / h from - [4- (N-methylamino) -

3-amino-phenyl] -2-methyl-3- (1H-tetrazol-5-yl) -1-pyrrolidino-propan-1-one, 4-cyano-phenylglycine / O- (benzotriazol-1-yl) - N , N, N ', N' -tetramethyluronium tetrafluoroborate and subsequent treatment with glacial acetic acid. Yield: 17% of theory,

R _f value: 0.25 (silica gel; methylene chloride / ethanol = 9: 1) C ₂₅ H ₂₇ N ₉ 0 (469.55) mass spectrum: (MH) ^" = 468

f. 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (1H-tetrazol-5-yl-methyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole hydrochloride Prepared analogously to Example 11 from 2- (4-cyanophenylamino-methyl) -l-methyl-5- [1- (1H-tetrazol-5-yl-methyl) -1- (pyrrolidinocarbonyl) -ethyl] -benzimidazole and hydrochloric acid / ammonium car - bonat in ethanol. Yield: 25% of theory,

R _f value: 0.35 (reversed phase RP8; 5% saline / methanol = 1: 1) C ₂₅ H ₃₀ N ₁₀ OX HC1 (486.58 / 523.05) mass spectrum: (M + H) ⁺ = 487

In game 7

2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonyl-methylaminomethyl) -1- (pyrrolidinocarbonyl) -ethyl] -benzimidazole diacetate a. 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-

3-azido-l-pyrrole idin.o-propan-1-one

Prepared analogously to Example 6b from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-methanesulfonyloxy-l-pyrrolidino-propan-1-one and sodium azide in dimethylformamide. Yield: 100% of theory,

R _£ value: 0.75 (silica gel; ethyl acetate / petroleum ether = 1: 1) C ₂₂ H ₂₆ N ₆ 0 ₃ (422.49) mass spectrum: M ⁺ = 422

b. 2- [4- (N-Benzyl-methylamino) -3-nitro-phenyl] -2-methyl- - mino-1-pyrrole idino-propan-1-one

A solution of 24.75 g (59 mmol) of 2- [4- (N-benzyl-methylamino) - 3 -nitro-phenyl] -2-methyl-3-azido-l-pyrrolidino-propan-l-one and 15.7 g ( 60 mmol) triphenylphosphine in 250 ml tetrahydrofuran and 1.8 ml water is stirred for 60 hours at room temperature. After evaporation of the solvent, the residue is purified on silica gel, eluting initially with methylene chloride, later with methylene chloride / ethanol (50: 1, 9: 1, 8: 2 and 7: 3). The uniform fractions are combined and evaporated. Yield: 21.7 g (93% of theory), R _f value: 0.25 (reversed phase RP8; 5% saline / metha- nol = 2: 3) C ₂₂ H ₂₈ N ₄ 0 ₃ (396.49) mass spectrum: (M + H) ⁺ = 397

c. 2- [4- (N-Benzyl-methylamino) -3 -nitro-phenyl] -2 -methyl - -ter

Prepared analogously to Example 1c from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-amino-1-pyrrolidino-propan-1-one and di-tert. Butyl dicarbonate / N -Ethyl-diisopropylamine in dioxane.

Yield: 98% of theory,

R _f value: 0.55 (silica gel; methylene chloride / ethanol = 19: 1) C ₂₇ H ₃₆ N ₅ 0 ₄ (496.61) mass spectrum: M ⁺ = 496

(M + Na) ⁺ = 519

(MH) ^" = 495

d. 2- [4- (N-methylamino) -3-amino-phenyl] -2-methyl-3-tert-butyl-oxycarbonylami.no-1-pyrrolidino-propan-l-one

Prepared analogously to Example lf from 2- [4- (N-benzyl-methylamino) -3-nitro-phenyl] -2-methyl-3-tert. Butyloxycarbonylamino-1-pyrrolidino-propan-l-one and hydrogen / palladium on activated carbon ,

Yield: 23% of theory,

R _f value: 0.4 (silica gel; methylene chloride / ethanol = 19: 1) C ₂₀ H ₃₂ N ₄ O ₃ (376.5) mass spectrum: (M + Na) ⁺ = 399

(MH) ^" = 375

e. 2- (4-Cyanophenylaminomethyl) -l-methyl-5- [1- (tert -butyloxycarbonylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimizazole.

Manufactured analogously to example lg / h from 2- [4- (N-methylamino) -

3-amino-phenyl] -2-methyl-3- (tert-butyloxycarbonylamino) -1-pyrrolidino-propan-1-one, 4-cyano-phenylglycine / carbonyldiimidazole and subsequent treatment with glacial acetic acid. Yield: 58% of theory, R _f value: 0.5 (aluminum oxide; methylene chloride / ethanol = 19: 1) C ₂₉ H ₃₆ N ₆ 0 ₃ (516.65) mass spectrum: M ⁺ = 516

(M + Na) ⁺ = 539

f. 2- (4-cyanophenylaminomethyl) -l-methyl-5- [1-aminomethyl-

1 - (pyrrole i nocarbony) ethyll benzimidazole

Prepared analogously to example li from 2- (4-cyanophenylaminomethyl) -l-methyl-5- [1- (tert. Butyloxycarbonylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole and 6N hydrochloric acid in dioxane.

Yield: 82% of theory, R _f value: 0.25 (silica gel; methylene chloride / ethanol = 9: 1)

G. 2- (4-Cyanophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylamomethyl) -1- (pyrrole dincarbonyl) -ethyll -benzimidazole Prepared analogously to Example lk from 2- (4-cyanophenylamino-me- thyl) -l-methyl-5- [1-aminomethyl-l- (pyrrolidinocarbonyl) ethyl] benzimidazole and ethyl bromoacetate / potassium carbonate in acetone.

Yield: 25% of theory,

R _f value: 0.6 (silica gel; methylene chloride / ethanol = 9: 1)

C ₂₈ H ₃₄ N ₆ 0 ₃ (502.62)

Mass spectrum: (M + H) ⁺ = 503

(M + Na) ⁺ = 525

(MH) ^" = 501

H. 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylaminomethyl) -1- (pyrrolidinocarbonyl) -ethyl] -benzidazole -diacetate

Prepared analogously to Example 11 from 2- (4-cyanophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole and hydrochloric acid / ammonium carbonate in ethanol. Yield: 66% of theory,

R _f value: 0.35 (silica gel; methylene chloride / ethanol = 4: 1 + 1% glacial acetic acid) C ₂₈ H ₃₇ N ₇ 0 ₃ X 2 CH ₃ COOH (519.65 / 639.76) mass spectrum: (M + H) ⁺ = 520

The following compounds are obtained analogously to Example 7:

(1) 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (N- (2-ethoxycarbonylethyl) -N-methylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

(2) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (N-ethoxycarbonylmethylsulfonyl) -N-methylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

(3) 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (N-ethoxycarbonylmethylaminocarbonyl-N-methylaminomethyl) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole -hydrochorid

Yield: 55% of theory,

R _f value: 0.4 (reversed phase RP8; 5% saline / methanol

= 1: 1) C ₃₀ H _3B N ₈ 0 ₄ X HC1 (574.36 / 610.81) mass spectrum: (M + H) ⁺ = 575

(MH) ^" = 573

(M + Cl) ^" = 609/611 (Cl)

Example 8

(R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- [(R, S) -2-methyl-pyrrolidinocarbonyl] ethyl] -benz-i idazole dihydrochloride (mixture of diastereomers)

A solution of 500 mg (0.84 mmol) of (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (ethoxycarbonylmethylamino) - 1- [(R, S) -2-methyl-pyrrolidinocarbonyl ] -ethyl] -benzimidazole - dihydrochloride (mixture of diastereomers) in 4 ml of water is mixed with 2.7 ml of 1N sodium hydroxide solution and stirred for 45 minutes at room temperature. The pH of the solution is adjusted to 3.5 by adding IN hydrochloric acid. The solution is evaporated with the addition of toluene and the residue is washed with a little metha- nol offset. After filtering off the undissolved inorganic material, the filtrate is evaporated and triturated with ether. The solid formed is filtered off and dried. Yield: 480 mg (100% of theory), R _f value: 0.5 (reversed phase RP8; 5% saline / methanol

= 1: 1) C ₂₆ H ₃₃ N ₇ 0 ₃ X 2 HC1 (491.6 / 564.51) mass spectrum: (M + H) ⁺ = 492

(M + Na) ⁺ = 514

The following compounds are obtained analogously to Example 8:

(1) 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole dihydrochloride

Yield: 70% of theory,

R _f value: 0.45 (reversed phase RP8; 5% saline / methanol = 1: 1) C _2S H ₃₃ N ₇ 0 ₃ χ.2 HC1 (491.6 / 564.51) mass spectrum: (M + H) ⁺ = 492

(2) 2- (4-Amidinophenylaminomethyl) -1-methyl-5- [1- (carboxymethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole dihydrochloride

Yield: 100% of theory,

R _f value: 0.5 (reversed phase RP8; 5% saline / methanol

= 1: 1) C ₂₅ H ₂₉ N ₇ 0 ₃ X 2 HCl (475.55 / 548.46) mass spectrum: (M + H) ⁺ = 476

(MH) ^" = 474

(3) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] - l-methyl-5- [1- (carboxymethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

Yield: 67% of theory,

R _f value: 0.46 (silica gel; 5% methylene chloride / methanol / concentrated ammonia = 4: 0.9: 0.1) C ₃₂ H _3S N ₇ 0 ₄ (581.67)

Mass spectrum: (M + H) ⁺ = 582

(MH) ^" = 580

(M + Na) ^* = 604

(4) 2- (4-amidinophenylaminomethyl) -1-methyl-5- [1- (carboxymethyloxymethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole hydrochloride

Yield: 45% of theory,

R _f value: 0.4 (reversed phase RP8; 5% saline / methanol

= 1: 1) C ₂₆ H ₃₂ Ng0 ₄ x HC1 (492.58 / 529.03) mass spectrum: (M + H) "= 493

(MH) ^" = 491

(5) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (N- (2-carboxyethyl) -N-methylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

(6) 2- (4-Amidinophenylaminomethyl) -l-methyl-5- [1- (N-carboxymethylsulfonyl -N-methylaminomethyl) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole

(7) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (N-carboxy-methyaminocarbonyl) -N-methylaminomethyl) -1- (2,5-dihydropyrrolocarbonyl) ethyl] - benzimidazole hydrochloride Yield: 15% of theory,

R _f value: 0.5 (reversed phase RP8; 5% saline / methanol

= 1: 1) C ₂₈ H ₃₄ N ₈ 0 ₄ X HC1 (546.62 / 583.09) mass spectrum: (M + H) ⁺ = 547

(MH) ^" = 545

(M + Cl) ^" = 581/583 (Cl)

Example 2.

Dry ampoule with 75 mg wi per 10 ml Composition:

Active ingredient 75.0 mg

Mannitol 50.0 mg

Water for I j ection purposes ad 10.0 ml

production:

Active ingredient and mannitol are dissolved in water. After filling, freeze-drying. The ready-to-use solution is dissolved with water for injections.

example 1

Dry ampoule. with 35 mg of active ingredient per 2 ml

Composition:

Active ingredient 35.0 mg

Mannitol 100.0 mg

Water for injections ad 2.0 ml

production:

Active ingredient and mannitol are dissolved in water. After filling, freeze-drying.

The ready-to-use solution is dissolved with water for injection purposes.

When playing] 11

Tablet with 50 mg of active ingredient

Composition:

(1) Active ingredient 50.0 mg

(2) milk sugar 98.0 mg (3) corn starch 50.0 mg

(4) Polyvinylpyrrolidone 15.0 mg

(5) Magnesium stearate 2.0 mg

215.0 mg

production:

(1), (2) and (3) are mixed and granulated with an aqueous solution of (4). (5) is added to the dried granulate. Tablets are pressed from this mixture, biplan with a facet on both sides and a partial notch on one side. Tablet diameter: 9 mm.

Example 12

Tablet with 350 mg of active ingredient

Composition:

(1) Active ingredient 350.0 mg

(2) milk sugar 136.0 mg

(3) corn starch 80.0 mg

(4) polyvinyl pyrrolidone 30.0 mg

(5) Magnesium stearate 4.0 mg

600.0 mg

production:

(1), (2) and (3) are mixed and granulated with an aqueous solution of (4). (5) is added to the dried granulate. Tablets are pressed from this mixture, biplan with a facet on both sides and a partial notch on one side. Tablet diameter: 12 mm.

Example] 13.

Capsule with 50 mg active ingredient

Composition: (1) Active ingredient 50.0 mg

(2) Corn starch dried 58.0 mg

(3) Milk sugar powdered 50.0 mg

(4) Magnesium stearate 2.0 mg

160.0 mg

production:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing.

This powder mixture is filled into size 3 hard gelatin capsules on a capsule filling machine.

Example 14

Capsules with 350 mg of active ingredient

Composition:

(1) Active ingredient 350.0 mg

(2) Corn starch dried 46.0 mg

(3) Milk sugar powdered 30.0 mg

(4) Magnesium stearate 4.0 mg

430.0 mg

production:

(1) is triturated with (3). This trituration is added to the mixture of (2) and (4) with intensive mixing.

This powder mixture is filled in a size 0 hard gelatin capsule on a capsule filling machine.

Example 15.

Suppositories with 100 mg of active ingredient 1 suppository contains:

Active ingredient 100.0 mg

Polyethylene glycol (M.G. 1500) 600.0 mg Polyethylene glycol (M.G. 6000) 460.0 mg Polyethylene sorbitan monostearate 840.0 mg

2,000.0 mg

production:

The polyethylene glycol is melted together with polyethylene sorbitan monostearate. The milled active substance is homogeneously dispersed in the melt at 40 ° C. It is cooled to 38 ° C and poured into weakly pre-cooled suppository molds.

Claims

claims

1. Benzimidazoles of the general formula

in the

R _{a is} a straight-chain C _1-3 alkyl group in which the hydrogen atoms can be replaced in whole or in part by fluorine atoms and in the 1-position

by a pyrrolidinocarbonyl or 2, 5-dihydropyrrolo carbonyl group optionally substituted by a C ₃ alkyl group and

by an amino group which is replaced by a carboxy-C ₁ . _4- alkyl, cyano-C ₁ " _4- alkyl or tetrazolyl-C ₁ . ₄ -alkyl group ^{• is} mono-substituted,

or by a C 1 -C 4 -alkyl group which is terminated by a C ₁ _, optionally on one or both amine nitrogen atoms. ₃ -Al yl groups substituted N- (carboxy-C _1-3 -alkylaminocarbonyl) -amino group, by a carboxy-C ^ -alkoxy-, N- (carboxy-C ₁ _ ₃ -alkyl) -amino-, N- (C ^ -Alkyl) -N- (carboxy-C _{1, 3-} alkyl) -amino-, N- (carboxy-C _{1, 3-} alkylsulfonyl) -amino-, N- (C ^ -alkyl) -N- (carboxy - C _{1, 3} -alkylsulfonyl) amino or tetrazolyl-C _{λ 3} alkyl group is substituted,

R _{b is} a C _j __ ₃ alkyl group and R _{c is} an amidino group, a cyano group or a 1,2,4-oxadiazol-3-yl group substituted in the 5-position by a C 1-4 alkyl or phenyl group, the phenyl substituent being substituted by a fluorine, chlorine or bromine atom or by a C _x . ₃ alkyl group may be substituted,

their tautomers, their stereoisomers, their mixtures, their prodrugs, their derivatives which, instead of a carboxy group, contain a group which is negatively charged under physiological conditions, and their salts.

2. Benzimidazoles of the general formula I according to claim 1, in which

R _b and R _{c are} as defined in claim 1 and

R _{a is defined} with the proviso that a substituent represents a non-branched C 1-4 alkyl group or a 2,5-dihydropyrrolocarbonyl group which is optionally substituted by a C _1-3 alkyl group,

or R _{a is} an ethyl group which is in the 1-position

by a pyrrolidinocarbonyl group and

is substituted by an amino group, the amino group by an ethoxycarbonylmethyl group which is substituted in the ethoxy part in the 2-position by a methoxy, dimethylamino or tolyl group by a carboxymethyl, C ₃ . ₄ -Alkoxycarbonylmethyl-, cyclohexyloxycarbonyl methyl-, 3- (C. _{2 3} alkoxycarbonyl) propyl or tetrazolyl methyl group is substituted,

R _{b is} a methyl group and R _c is an amidino group substituted by a benzoyl, methylbenzoyl, fluorobenzoyl or trifluoromethylbenzoyl group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group substituted in the 2-position by a methyl group and

is substituted by an amino group, the amino group being substituted by a carboxymethyl or ethoxycarbonylmethyl group,

R _{b is} a methyl group and

R _{c is} an amidino group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group and

by an amino group substituted by a carboxymethyl, C _3-4 alkoxycarbonylmethyl or tetrazolylmethyl group or

is substituted by a methyl group, the methyl group being replaced by a tetrazolyl, carboxymethoxy, ethoxycarbonylmethoxy, ethoxycarbonylmethylamino, N- (2-carboxyethyl) -N-methylamino, N- [2- (C _{1. 3} -Alkoxycarbonyl) -ethyl] - N-methylamino-, N- (carboxymethylaminocarbonyl) -N-methylamino-, N- (C ^ -alkoxycarbonylmethylaminocarbonyl) -N-methylamino-, N- (carboxymethylsulfonyl) -N-methylamino- or N- (Cj _^ ^ -alkoxycarbonylmethylsulfonyl) -N-methyl-amino group is substituted,

R _{b is} a methyl group and R _{c represents} an amidino group,

their tautomers, their isomers and their salts.

3. Benzimidazoles of the general formula I according to claim 2 with the exception of

(1) 2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (n-butyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole and

(2) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (tetrazol-5-yl-methylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole,

their tautomers, their isomers and their salts.

4. Benzimidazoles of the general formula I according to claim 1, in which

R _{a is} an ethyl group in the 1-position

by a 2, 5-dihydropyrrolocarbonyl group optionally substituted by a methyl group and

by an amino group which is replaced by a C ₁ . ₄ -alkoxycarbonyl- C ₁ . ₄ -alkyl group in which the C ₂ . ₄ -alkoxy part may be terminally substituted by a methoxy, dimethylamino, phenyl or tolyl group, by a carboxy-C., _ ₄ -alkyl, cyclohexyloxycarbonyl-C ^ alkyl or tetrazolyl - C _x _ ₄ -alkyl group is monosubstituted, or

by a C _1-3 alkyl group, terminally ^ by an optionally atoms at one or two amine nitrogen in each case by a C alkyl substituted N- (carb bonyl-C ₁ _ ₃ -alkylaminocarbonyl) -amino group, by a carboxy-C _τ _ ₃ -alkoxy-, C ^ -alkoxycarbonyl-C _1-3 -alkoxy-, N- (C _1-3 -AI- kyl) -N- (carboxy-C _{1, 3} -alkyl) -amino-, N- (C 1-4 alkyl) - N- (C ₁ _ ₃ -alkoxycarbonyl-C ₁ _ ₃ -alkyl) -amino-, N - (. C _{1 3} alkyl) - N- (carboxy-C ^ -alkylsulfonyl) amino or N- (C - ^ - alkyl) - N- (C ^ alkoxycarbonyl-C ^ alkylsulfonyl) amino or tetrazolyl-C _1-3 alkyl group is substituted,

R _{b is} a methyl group and

R _c is an amidino group which may be substituted by a benzoyl, methylbenzoyl, fluorobenzoyl or trifluoromethylbenzoyl group

or R _{a is} an ethyl group which is in the 1-position

by a pyrrolidinocarbonyl group and

is substituted by an amino group, the amino group being substituted by an ethoxycarbonylmethyl group which is substituted in the 2-position by a methoxy, dimethylamino or tolyl group, by a carboxymethyl, propyloxycarbonylmethyl, isopropyloxycarbonylmethyl, isobutyloxycarbonylmethyl, Cyclohexyloxycarbonylmethyl, 3- (C ₂ _ ₃ -alkoxycarbonyl) propyl or tetrazolylmethyl group is substituted,

R _{b is} a methyl group and

R _c is an amidino group substituted by a benzoyl, methylbenzoyl, fluorobenzoyl or trifluoromethylbenzoyl group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group substituted in the 2-position by a methyl group and is substituted by an amino group, the amino group being substituted by a carboxymethyl or ethoxycarbonylmethyl group,

R _{b is} a methyl group and

R _{c is} an amidino group or

R _{a is} an ethyl group in the 1-position

by a pyrrolidinocarbonyl group and

by one by a carboxymethyl or C ₃ . ₄ -alkoxycarbonylamino group substituted amino group or

is substituted by a methyl group, the methyl group being substituted by a tetrazolyl, carboxymethoxy, ethoxycarbonyl methoxy, ethoxycarbonylmethylamino, N- (2-carboxyethyl) -N-methylamino, N- [2- (C _{α 3} -alkoxycarbonyl) -ethyl] - N-methylamino-, N- (carboxymethylaminocarbonyl) -N-methylamino-, N- (C _1-3 -alkoxycarbonylmethylaminocarbonyl) -N-methylamino-, N- (carboxymethylsulfonyl) -N -methylamino or N- (C ₁ _ ₃ -alkoxycarbonylmethylsulfonyl) -N-methylamino group is substituted,

R _{b is} a methyl group and

R _{c represents} an amidino group,

their tautomers, their isomers and their salts.

5. The following benzimidazoles of the general formula I according to claim 1:

(1) 2- (-amidinophenylaminomethyl) -1-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole, (2) 2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -l-methyl-5- [1- (ethoxycarbonylmethylamino) -1- (2,5-dihydropyrrolo-carbonyl) ethyl] benzimidazole,

(3) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (isobutyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole,

(4) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (n-propyloxycarbonylmethylamino) -1- (pyrrolidinocarbonyl) ethyl] benzimidazole,

(5) (R) -2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- [(R, S) -1-methylpyrrolidinocarbonyl] ethyl] benzimidazole .

(6) 2- (4-amidinophenylaminomethyl) -l-methyl-5- [1- (carboxymethylamino) -1- (2,5-dihydropyrrolocarbonyl) ethyl] benzimidazole and

(7) (R) -2- [4- (N-phenylcarbonylamidino) phenylaminomethyl] -1-methyl-5- [1- (cyclohexyloxycarbonylmethylamino) -1 - (2,5-di-hydropyrrolocarbonyl) ethyl] benzimidazole .

their isomers and their salts.

6. Physiologically acceptable salts of the compounds according to claims 1 to 6, in which R _{c represents} one of the amidino groups mentioned in claims 1 to 5.

7. Medicament containing a compound according to at least one of claims 1 to 5, in which R _{c represents} one of the amidino groups mentioned in claims 1 to 5, or a salt according to claim 6 in addition to optionally one or more inert carriers and / or diluents ,

8. Use of a compound according to at least one of claims 1 to 5, in which R _{c represents} one of the amidino groups mentioned in claims 1 to 5, or a salt according to claim 6 for the manufacture of a medicament with an action which prolongs the thrombin time, an antithrombin action and an inhibitory effect on related serine proteases.

9. A process for the preparation of a medicament according to claim 7, characterized in that a compound according to at least one of claims 1 to 5, in which R _{c represents} one of the amidino groups mentioned in claims 1 to 5, or a salt according to claim 6 is incorporated into one or more inert carriers and / or diluents.

10. A process for the preparation of the compounds according to claims 1 to 6, characterized in that

a) for the preparation of a compound of general formula I in which R _{c is} a cyano group or a 1, 2, 4-oxadiazol-3-yl group which is substituted in the 5-position by a C 1-4 alkyl or phenyl group, the Phenyl substituent can be substituted by a fluorine, chlorine or bromine atom or by a C ₃ alkyl group,

a compound of the general formula optionally formed in the reaction mixture

* b in the

R _a and R _{b are} as defined in claims 1 to 5, R _c 'is a cyano group or one in the 5-position by a C ₁ . ₃ -alkyl or phenyl group substituted 1, 2, 4-oxadiazol-3-yl group, where the phenyl substituent can be substituted by a fluorine, chlorine or bromine atom or by a C 1-4 alkyl group,

Z and Z ₂ , which may be the same or different, amino, hydroxyl or mercapto groups optionally substituted by alkyl groups having 1 to 6 carbon atoms or Z and Z ₂ , together an oxygen or sulfur atom, one optionally substituted by an alkyl group with 1 to 3 Carbon atoms substituted imino group, an alkylenedioxy or alkylenedithio group each having 2 or 3 carbon atoms, is cyclized or

b) for the preparation of a compound of the general formula I in which R _{c represents} an amidino group,

a compound of the general formula optionally formed in the reaction mixture

in the

R _a and R _{b are} as defined in claims 1 to 5 and

Z _{4 is} an alkoxy, aralkoxy, alkylthio or aralkylthio group, is reacted with ammonia or with its salts, or

c) for the preparation of a compound of the general formula I in which R _a contains a carboxy group and R _{c is} as defined in claims 1 to 5,

a compound of the general formula

Rb in the

R _b and R _{c are} as defined in claims 1 to 5 and

R _a 'has the meanings mentioned for R _a in claims 1 to 5 with the proviso that R _a contains a group which can be converted into a carboxy group by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis,

by hydrolysis, treatment with an acid or base, thermolysis or hydrogenolysis in a compound of general formula I, in which R _a contains a carboxy group, is converted or

d) for the preparation of a compound of the general formula I in which R _{c represents} an amidino group which is substituted by a radical which can be split off in vivo,

a compound of the general formula

R, - in the

R _a and R _{b are} as defined in claims 1 to 5, with a compound of the general formula

Z ₅ - R ₉ (VII),

in the R _{9 is} the acyl residue of one of the residues which can be split off in vivo and is mentioned in claims 1 to 5

Z _{5 represents} a nucleofugic leaving group, is implemented or

e) for the preparation of a compound of the general formula I in which R _{c represents} one of the amidino groups mentioned in claims 1 to 5,

a compound of the general formula

in the

R _a and R _{b are} as defined in claims 1 to 5 and

R _c "represents a 1, 2, 4-0xadiazol-3-yl group substituted in the 5-position by a C 1-4 alkyl or phenyl group, in which the phenyl substituent is represented by a fluorine, chlorine or bromine atom or by a C. _{1, 3} -alkyl group can be substituted, catalytically hydrogenated and, if necessary, a compound thus obtained is then hydrolyzed or

f) for the preparation of a compound of general formula I, in which R _{a represents} an amino-C ^ alkyl group in which the amino group by a carboxy-C ^ alkyl or tetrazolyl C ₁ . ₄ -alkyl group is monosubstituted,

a compound of the general formula in the

R _b and R _{c are defined} as in claims 1 to 5 and

R _a "represents an amino-C _x . ₃ -alkyl group, with a compound of the general formula

R. (X)

in the

R _a "'is a carboxy-C _1-4 alkyl or tetrazolyl ^ alkyl group and

Z _{7 represents} a nucleofugic leaving group, is alkylated and

if desired, a compound of the general formula I thus obtained, in which R _a contains a carboxy group, is subsequently converted by esterification into a corresponding compound in which R _{a contains} an esterified carboxy group and / or

a compound of the general formula I thus obtained, in which R _{a contains} an esterified carboxy group, is converted by transesterification into a corresponding compound in which R _a contains another esterified carboxy group, and / or

a compound of the general formula I obtained in this way, in which R _a contains a cyano group, is converted into a corresponding compound in which R _{a contains} a tetrazolyl group using nitrogen-hydrochloric acid, and / or

a protective residue used during the reactions to protect reactive groups is split off and / or a compound of the general formula I thus obtained is separated into its stereoisomers and / or

a compound of the general formula I thus obtained is converted into its salts, in particular for pharmaceutical use into its physiologically tolerable salts with an inorganic or organic acid or base.